CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-02 | Christmas Patrick J. Chief Legal Officer | Option exercise | +10,000 | $12.10 | $121K | 26,372 |
| 2021-02-02 | Christmas Patrick J. Chief Legal Officer | Sale | −9,500 | $44.77 | $425K | 16,872 |
| 2021-02-02 | Christmas Patrick J. Chief Legal Officer | Sale | −500 | $45.13 | $23K | 16,372 |
| 2021-02-02 | Christmas Patrick J. Chief Legal Officer | Option exercise · Employee Stock Option (Right to Buy) | −10,000 | 12,431 | ||
| 2021-01-25 | Mills Kenneth T. President and CEO | Option exercise | +6,500 | $0.85 | $6K | 287,484 |
| 2021-01-25 | Mills Kenneth T. President and CEO | Sale | −315 | $42.64 | $13K | 287,169 |
| 2021-01-25 | Mills Kenneth T. President and CEO | Sale | −974 | $44.05 | $43K | 286,195 |
| 2021-01-25 | Mills Kenneth T. President and CEO | Sale | −5,211 | $44.99 | $234K | 280,984 |
| 2021-01-25 | Mills Kenneth T. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −6,500 | 41,170 | ||
| 2021-01-15 | Vasista Vittal Chief Financial Officer | Sale | −252 | $50.04 | $13K | 113,640 |
| 2021-01-14 | Simpson Curran Chief Oper. & Tech. Officer | Option exercise | +1,240 | $19.50 | $24K | 18,988 |
| 2021-01-14 | Simpson Curran Chief Oper. & Tech. Officer | Option exercise | +10,372 | $35.80 | $371K | 29,360 |
| 2021-01-14 | Simpson Curran Chief Oper. & Tech. Officer | Sale | −11,612 | $50.01 | $581K | 17,748 |
| 2021-01-14 | Simpson Curran Chief Oper. & Tech. Officer | Option exercise · Stock Option (Right to Buy) | −1,240 | 0 | ||
| 2021-01-14 | Simpson Curran Chief Oper. & Tech. Officer | Option exercise · Stock Option (Right to Buy) | −10,372 | 17,128 | ||
| 2021-01-14 | Vasista Vittal Chief Financial Officer | Sale | −11,093 | $50.03 | $555K | 113,892 |
| 2021-01-12 | Simpson Curran Chief Oper. & Tech. Officer | Option exercise | +1,700 | $19.50 | $33K | 19,448 |
| 2021-01-12 | Simpson Curran Chief Oper. & Tech. Officer | Sale | −1,700 | $50.03 | $85K | 17,748 |
| 2021-01-12 | Simpson Curran Chief Oper. & Tech. Officer | Option exercise · Stock Option (Right to Buy) | −1,700 | 1,240 | ||
| 2021-01-12 | Vasista Vittal Chief Financial Officer | Sale | −4,200 | $50.01 | $210K | 124,985 |
Page 18 of 25 · 494 trades